Identification and validation of a five MicroRNA signature predictive of prostate cancer recurrence and metastasis: A cohort study

Journal of Cancer

Volumn 6, Issue 11, 2015, Pages 1160-1171

  Nam, Robert K ^a   Amemiya, Yutaka ^a   Benatar, Tania ^a   Wallis, Christopher J D ^a   Stojcic Bendavid, Jessica ^a   Bacopulos, Stephanie ^a   Sherman, Christopher ^b   Sugar, Linda ^b   Naeim, Magda ^b   Yang, Wenyi ^a   Zhang, Aiguo ^a   Klotz, Laurence H ^a   Narod, Steven A ^a   Seth, Arun ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Canada   (Canada)

Author keywords

High throughput nucleotide sequencing; MicroRNA; Prostatectomy; Prostatic neoplasms

Indexed keywords

KERATIN; MICRORNA; MICRORNA 1248; MICRORNA 1249; MICRORNA 1302; MICRORNA 1302 1; MICRORNA 1302 3; MICRORNA 139; MICRORNA 154; MICRORNA 188; MICRORNA 18A; MICRORNA 205; MICRORNA 223; MICRORNA 301A; MICRORNA 301B; MICRORNA 34B; MICRORNA 34C; MICRORNA 411; MICRORNA 433; MICRORNA 452; MICRORNA 454; MICRORNA 489; MICRORNA 497; MICRORNA 501; MICRORNA 545; MICRORNA 624; MICRORNA 652; MICRORNA 671; MICRORNA 708; MICRORNA 9; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE METASTASIS; PROSTATECTOMY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA SEQUENCE; UPREGULATION; VALIDATION STUDY;

EID: 84947779451     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13397     Document Type: Article

References (41)

1. Nam RK, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. The lancet oncology. 2014;15(2):223-31.
2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA: the journal of the American Medical Association. 1998;280(11):969-74.
3. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
5. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. The Journal of urology. 2014;192(1):252-9.
6. Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014;33(44):5173-82.
7. Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PloS one. 2013;8(6):e65064.
8. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. International journal of cancer Journal international du cancer. 2010;127(2):394-403.
9. Nam RK, Zhang WW, Siminovitch KA, Kattan MW, Seth A, Klotz LH, et al. New Variants at 10q26 and 15q21 Are Associated With Aggressive Prostate Cancer in a Genome-Wide Association Study from a Prostate Biopsy Screening Cohort. Cancer, Biology and Therapy. 2011;12(11):997-1004.
10. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. The New England journal of medicine. 2004;350(18):1828-37.
11. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer cell. 2008;13(1):48-57.
12. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011;71(8):2926-37.
13. Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, et al. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell biochemistry and function. 2013;31(4):319-24.
14. Guo H, Hu X, Ge S, Qian G, Zhang J. Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. The international journal of biochemistry & cell biology. 2012;44(9):1465-72.
15. Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, et al. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochemical pharmacology. 2012;84(3):320-30.
16. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140(1):322-31.
17. Siadat F, Sykes J, Zlotta AR, Aldaoud N, Egawa S, Pushkar D, et al. Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. The Prostate. 2015.
18. Jung JW, Lee JK, Hong SK, Byun SS, Lee SE. Stratification of patients with intermediate-risk prostate cancer. BJU international. 2015;115(6):907-12.
19. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. The Journal of urology. 2013;190(2):441-9.
20. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(1 Suppl):S2-S11.
21. Song C, Chen H, Wang T, Zhang W, Ru G, Lang J. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate. 2015.
22. Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, et al. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem. 2013;59(11):1595-603.
23. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. European urology. 2011;59(6):893-9.
24. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Molecular cancer. 2006;5:29.
25. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005;334(4):1351-8.
26. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. Journal of gastroenterology and hepatology. 2009;24(4):652-7.
27. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-70.
28. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537-45.
29. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753-6.
30. Chen Z, Chen LY, Dai HY, Wang P, Gao S, Wang K. miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem. 2012;113(10):3229-35.
31. Liu L, Nie J, Chen L, Dong G, Du X, Wu X, et al. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PloS one. 2013;8(2):e55532.
32. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, et al. miR-301a as an NF-kappaB activator in pancreatic cancer cells. The EMBO journal. 2011;30(1):57-67.
33. Wang M, Li C, Yu B, Su L, Li J, Ju J, et al. Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. Journal of gastroenterology. 2013;48(9):1023-33.
34. Xu XD, He XJ, Tao HQ, Zhang W, Wang YY, Ye ZY, et al. Abnormal expression of miR-301a in gastric cancer associated with progression and poor prognosis. J Surg Oncol. 2013;108(3):197-202.
35. Zhou P, Jiang W, Wu L, Chang R, Wu K, Wang Z. miR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma. Digestive diseases and sciences. 2012;57(5):1171-80.
36. Xie H, Li L, Zhu G, Dang Q, Ma Z, He D, et al. Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-beta1/Smad/MMP9 signals. Oncotarget. 2015.
37. Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y, et al. Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/beta-catenin signaling. Gene. 2014;535(2):191-7.
38. Zhang W, Zhang T, Jin R, Zhao H, Hu J, Feng B, et al. MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res. 2014;33(1):780.
39. Tsuchiyama K, Ito H, Taga M, Naganuma S, Oshinoya Y, Nagano K, et al. Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. Prostate. 2013;73(8):827-34.
40. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. Journal of Cancer. 2013;4(5):350-7.
41. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. The Journal of clinical investigation. 2013;123(11):4918-22.